mRNA Synthesis and Manufacturing Services Market Size, Share and Growth Analysis 2025 to 2034
Global mRNA Synthesis and Manufacturing Services Market Size is valued at USD 958.52 Mn in 2024 and is predicted to reach USD 2,294.90 Mn by the year 2034 at a 7.7% CAGR during the forecast period for 2025 to 2034.
In 2024 market has grown exponentially due to the success of the COVID-19 vaccines, and it has created a massive demand for a consistent supply of vaccines. However, in 2022 market is expected to decrease at the growth rate of -42.0%. The mRNA Synthesis and Manufacturing Services market other than COVID 19 application are under development which offers immense growth and penetration opportunities in the forecast period. By region, Asia Pacific dominates the mRNA synthesis and manufacturing services market with share of 33.4% of total global market.

Due to its versatile and flexible nature, mRNA is an excellent platform for developing prophylactic or therapeutic vaccines against various chronic and infectious diseases. Compared to conventional medicines, mRNA vaccines have higher effectiveness, improved immunogenicity, and required less manufacturing cost. The constant innovations and improvements in mRNA synthesis and manufacturing services are expected to propel the market growth of mRNA synthesis and manufacturing services over the forecast period. During the current Covid-2019 pandemic, many companies have chosen mRNA vaccine technology to combat coronavirus.
For instance, in November 2020, Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
The increasing need for gene therapies, growing chronic and infectious diseases, and the rising number of clinical trials for cancer therapies and infectious diseases are likely to evolve the mRNA synthesis and manufacturing services market at a considerable rate in the next few years. Furthermore, advanced medical technologies, increasing customizable facilities, improving quality and efficacy services, and novel innovations by pharmaceutical companies enhance the market growth.
However, the lack of flexible, sustainable, and cost-effective manufacturing processes hinders the growth of mRNA synthesis and manufacturing services.Segmentation of mRNA synthesis and manufacturing services market includes Products, Applications, Scale of Operation, and Region. The market can be segmented into API and Drug Products based on Products. By Applications, the market is categorized into Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others. Based on the Scale of Operation, the market is segmented into Research / Preclinical, Clinical, and Commercial. Regionally, the mRNA synthesis and manufacturing services market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe and the Asia Pacific, holds the maximum share of this market due to increased research and development expenditure, increased prevalence of infectious diseases, and the fast adoption of advanced technologies.
Recent Developments:
- In Sept 2023, Lonza and Touchlight have teamed up to deliver end-to-end solutions for mRNA.Through this collaboration, Lonza can expand its end-to-end offering for mRNA manufacture by providing an additional and differentiated supply of DNA raw material in the form of Touchlight's doggybone DNA (dbDNATM). Touchlight's synthetic DNA is produced using an enzymatic method that does not include the use of cells, resulting in increased speed, quality, capacity, and scalability.
- In Aug 2023, The United States granted Arcturus a financial award of $63.2 million, the company disclosed. To accelerate response efforts to the pandemic, the government will fund the development of a self-amplifying mRNA vaccine. Arcturus intends to augment its current influenza vaccine program with the assistance of the Biomedical Advanced Research and Development Authority. This expansion will encompass the creation of a pandemic influenza vaccine, which will be constructed upon the organization's exclusive self-amplifying mRNA platform. This undertaking will be executed utilizing the organization's current influenza vaccine program.
Competitive Landscape
Some major key players in the mRNA Synthesis and Manufacturing Services Market:
CDMO Organizations
- eTheRNA (Etherna Immunotherapies),
- Celonic AG
- Corden Pharma GmbH
- Lonza Group AG
- Rentschler Biopharma
- Laboratorios Farmacéuticos Rovi, S.A.
- Samsung Biologics
- Thermo Fisher Scientific
- Sartorius AG (BIA Separations)
- AGC Biologics
- FUJIFILM Diosynth Biotechnologies
- Hanmi Pharmaceutical
- Arranta Bio
- ST Pharm
- BioCina Pty Ltd.
- Curia Global, Inc.
Custom Synthesis/cGMP Service Providers:
- Eurogentec
- Aldevron
- bioSYNTHESIS
- TriLink BioTechnologies
- Biomay
- Jena Biosciences
- APExBIO
- CELLSCRIPT
- New England Biolabs
- Kernal Biologics
mRNA Synthesis and Manufacturing Services Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 958.52 Mn |
| Revenue Forecast In 2034 | USD 2,294.90 Mn |
| Growth Rate CAGR | CAGR of 7.7% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Industry, Application, Scale of operations, Product, Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; |
| Competitive Landscape | eTheRNA (Etherna Immunotherapies), Celonic AG, Corden Pharma GmbH, Lonza Group AG, Rentschler Biopharma, Laboratorios Farmacéuticos Rovi, S.A., Samsung Biologics, Thermo Fisher Scientific, Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio, ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of mRNA Synthesis and Manufacturing Services Market-
mRNA Synthesis and Manufacturing Services Market By Products-
- API
- Drug Products
mRNA Synthesis and Manufacturing Services Market By Type of Industry-
- Therapeutics and Vaccine Developers
- CDMO Organizations
- Custom Synthesis/Other Service Providers
mRNA Synthesis and Manufacturing Services Market By Therapeutic Area-
- Infectious Diseases
- Oncological Disorders
- Other Diseases
mRNA Synthesis and Manufacturing Services Market By Scale of Operation-
- Research / Preclinical
- Clinical
- Commercial
mRNA Synthesis and Manufacturing Services Market By Application-
- mRNA-based Vaccines
- mRNA-based Therapeutics
mRNA Synthesis and Manufacturing Services Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
CureVac, Moderna, BioNTech (Pfizer), Translate Bio, Ethris (AstraZeneca), Silence Therapeutics, Tiba Biotechnology, In-Cell-Art, Anima Biotech, H3 Bio
mRNA Synthesis and Manufacturing Services Market is expected to grow at a 7.7% CAGR during the forecast period for 2025 to 2034
mRNA Synthesis and Manufacturing Services Market Size is valued at USD 958.5 Mn in 2024 and is predicted to reach USD 2,294.9 Mn by year 2034
By Type of Industry, Application, Scale of operations, Product and Therapeutic Area are the key segments of the Iprodione Market.
North American region is leading the mRNA Synthesis and Manufacturing Services Market.